Tassos Georgiadis

Tassos Georgiadis has been working on gene therapy for 25 years. He has developed AAV vectors for a range of indications that are currently in clinical development (Phase 1/2, Phase 3, pre-commercialisation). He is currently Senior Vice President, Discovery & Preclinical Development at MeiraGTx, establishing a multi-platform assessment strategy for drug product candidate screening, with a focus on retina and CNS. Prior to joining MeiraGTx, he worked at the UCL Institute of Child Health and the UCL Institute of Ophthalmology, where he focused on ocular disorders and regulation of gene expression. He served on the UK Health Research Authority Research Ethics Committee, and on the Board of the British Society for Gene and Cell Therapy. He received a PhD in Molecular Genetics from University College London.